This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Mississippi
Licensed Mississippi practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Mississippi buyers need their own professional license and NPI; the wholesaler permit is the supplier’s obligation, not the purchaser’s.
Mississippi has widened its Right to Try Act twice since 2015, and the 2024 expansion reaches further into regenerative biology than any other state’s: it expressly includes products derived from human perinatal tissues, cells, and secreted factors. That phrase is worth reading carefully, because the framework it sits in is a patient-access law with strict gates, not a practice authorization.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Mississippi? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | SB 2485 (2015); SB 2527 (2016); SB 2858 (2024) (2024) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Mississippi
ExaVeyra ships to licensed practices in all 50 states, Mississippi included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Mississippi professional license in good standing, verifiable through the Mississippi State Board of Medical Licensure Provider Look-up or the Mississippi Board of Nursing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Mississippi sales tax permit from the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Mississippi permits wholesale distribution of prescription drugs through the Board of Pharmacy under section 73-21-105 of the Pharmacy Practice Act, which covers facilities where prescription drugs or devices are dispensed, sold, repackaged, or manufactured. The section is explicit about reach: any person located outside the state who distributes prescription drugs into Mississippi must obtain a permit from the board. The board posts the section text on its own site and administers the facility permit categories. The permit sits with the distributor, not with the purchasing practice.
Miss. Code Ann. § 73-21-105 · Mississippi Board of Pharmacy
Mississippi regenerative-medicine law
Mississippi enacted SB 2485 (2015); SB 2527 (2016); SB 2858 (2024), codified at Miss. Code Ann. § 41-131-1, effective 1 July 2024.
The Right to Try Act, enacted by SB 2485 in 2015 and codified at section 41-131-1, lets a physician prescribe or recommend an investigational drug, biological product, or device to an eligible patient. SB 2527 (2016) widened eligibility to patients with a debilitating disability, terminal illness, or life-threatening illness, and widened the product definition to anything described in an FDA or NIH approved protocol or study or approved by an institutional review board. SB 2858 (2024) added individualized investigational treatments for patients whose physician recommends one based on analysis of the patient’s own genomic sequence or related molecular profile, with licensing boards barred from disciplining a provider solely for the recommendation. Every pathway is gated on the treating physician and detailed written informed consent, and nothing in the lineage authorizes a product for general or aesthetic use.
- Patient access, not practice authorization: every pathway runs through a physician recommendation and written informed consent
- Right to Try Act eligibility: a debilitating disability, terminal illness, or life-threatening illness that approved products have not addressed
- Products in an FDA or NIH approved protocol or study, or approved by an institutional review board (2016 widening)
- Individualized investigational treatments produced exclusively for one patient from their own genetic profile (2024)
- Includes products derived from human perinatal tissues, cells, and secreted factors; excludes embryonic stem cell products
“"Individualized investigational treatment" includes, but is not limited to, individualized gene therapy antisense oligonucleotides (ASO) and individualized neoantigen vaccines. "Individualized investigational treatment" does not include any drug, biological product, or device derived from human primary or secondary embryonic stem cells or cell lines, or tissues or cells derived from abortion, but does include any drug, biological product, or device derived from human perinatal tissues, cells, and secreted factors not obtained from an abortion.”
How this applies to exosomes
Mississippi’s right-to-try lineage comes closer to exosome biology than any statute except Tennessee’s, and still does not reach it. The 2024 individualized-treatment definition includes products derived from human perinatal tissues, cells, and secreted factors, and exosomes are secreted factors in the ordinary scientific sense, but the enrolled bill never uses the words exosome or extracellular vesicle, and the definition only applies to treatments produced exclusively for one named patient from their own genetic profile, accessed through a physician recommendation and informed consent. A vialed exosome product supplied to a practice is none of those things. Exosome products in Mississippi remain governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Mississippi practice
Mississippi is a collaborative-agreement state, which is the practical thing to plan around. A nurse practitioner needs a formal collaborative agreement with a qualifying physician before practicing, the agreement designates the specific practice sites, and the quality improvement program it carries runs monthly, with the collaborating physician reviewing ten percent or twenty of the NP’s charts, whichever is less. An NP-led aesthetic practice therefore operates with a collaborating physician in place, not independently.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians are licensed by the Mississippi State Board of Medical Licensure, perform medical acts within their scope, and are the source of delegation and of the collaborative relationships the nursing rules require. The board runs a public Provider Look-up for verification. |
| NP / APRN | Mississippi nurse practitioners practice in a collaborative/consultative relationship with a physician who holds an unrestricted Mississippi license and a compatible practice, under Miss. Code Ann. 73-15-20 and Board of Nursing Part 2840. The relationship runs through a formal collaborative agreement naming the practice sites, with a quality improvement program that includes monthly review by the collaborating physician of a sample of the nurse practitioner’s charts. |
| PA | Physician assistants are licensed by the Mississippi State Board of Medical Licensure and practice under its supervision framework, within the scope their supervising physician establishes. |
| RN | Registered nurses practice under the Mississippi Nursing Practice Law and Board of Nursing rules, carrying out treatments on the order of a provider with authority to issue one. An RN does not evaluate the patient independently or set the treatment plan. |
Good faith examination
Mississippi expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. In an NP-run setting that evaluation happens inside the collaborative framework, with the collaborating physician’s chart review behind it. Confirm current expectations with the Mississippi State Board of Medical Licensure and the Mississippi Board of Nursing, since this area is governed by board rules rather than a single statute.
Ownership and clinic licensing
Mississippi does not codify a corporate practice of medicine prohibition in the way Texas or New York do, and no primary source stating a bright-line ownership rule was found. What is firmly documented is the practice-level control: an advanced practice nurse delivering medical services does so in a collaborative relationship with a physician, so a non-physician-owned entity still needs a physician in the clinical structure. Treat entity structure as a question for Mississippi counsel and the licensing boards.
Cold chain into Mississippi
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Mississippi order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Jackson | Hinds | Largest Mississippi market and the center of the state’s clinical infrastructure. |
| Ridgeland | Madison | North-metro corridor where much of the aesthetic segment concentrates. |
| Gulfport | Harrison | Coastal market served alongside Biloxi. |
| Hattiesburg | Forrest | Pine Belt hub with a university medical presence. |
| Oxford | Lafayette | North Mississippi market anchored by the university. |
| Tupelo | Lee | Northeast regional hub with a large hospital system. |
- Mississippi orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in Mississippi
Mississippi licensing and verification
Mississippi State Board of Medical Licensure
Licenses physicians and physician assistants; runs the Provider Look-up verification tool.
Mississippi Board of Nursing
Licenses APRNs, who practice under a collaborative agreement with a physician.
Mississippi Board of Pharmacy
Permits the wholesalers that distribute prescription drugs into Mississippi.
Mississippi Department of Revenue
Sales tax permits and registration.
Mississippi sourcing questions
- Does Mississippi have a stem cell law?
- Not a stem cell practice law. Mississippi has a Right to Try Act, codified at section 41-131-1 and widened in 2016 and 2024, which is a patient-access framework: a physician recommends an investigational product to an eligible patient who gives written informed consent. The 2024 individualized-treatment expansion expressly excludes embryonic stem cell products and includes products derived from human perinatal tissues, cells, and secreted factors, but it never names exosomes, and it does not authorize any product for general or aesthetic use.
- Does the 2024 Mississippi law cover exosomes?
- No. SB 2858 (2024) includes products derived from human perinatal tissues, cells, and secreted factors in its individualized-treatment definition, which is the closest any statute outside Tennessee comes to exosome biology, but the enrolled text never uses the words exosome or extracellular vesicle. The definition also only reaches treatments produced exclusively for one patient from their own genetic profile, accessed through a physician recommendation and informed consent. Exosome products remain governed by federal law, and no exosome product is FDA approved for administration to humans.
- What does a Mississippi nurse practitioner need in place?
- A formal collaborative agreement with a physician who holds an unrestricted Mississippi license and a compatible practice, under Miss. Code Ann. 73-15-20 and Board of Nursing Part 2840. The agreement designates the specific practice sites and carries a quality improvement program in which the collaborating physician reviews ten percent or twenty of the NP’s charts each month, whichever is less. The paperwork precedes the practice.
- Does my Mississippi clinic need a wholesaler permit to buy exosomes?
- No. The wholesaler permit under Miss. Code Ann. 73-21-105 is held by the distributor shipping into Mississippi, including any person located outside the state who distributes prescription drugs into it, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification about exosome products marketed outside that framework. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Mississippi?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Mississippi SB 2858 (2024), individualized investigational treatments, enrolled text as sent to the governor (accessed 16 October 2026)
- Mississippi SB 2485 (2015), the Right to Try Act, enrolled text (accessed 16 October 2026)
- Mississippi SB 2527 (2016), amending Miss. Code Ann. § 41-131-1 to expand eligibility (accessed 16 October 2026)
- Miss. Code Ann. § 73-21-105, wholesale distribution permits, as posted by the Board of Pharmacy (accessed 16 October 2026)
- Mississippi Board of Nursing, Part 2840, APRN rules including the collaborative agreement (accessed 16 October 2026)
- Mississippi Board of Pharmacy (accessed 16 October 2026)
- Mississippi Department of Revenue (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the baseline this page assumes when it distinguishes exosomes from the cells and tissues Mississippi’s statutes describe.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: The ISEV and ISCT position defining MSC-derived small extracellular vesicles, the scientific frame for this page’s reading of the statute’s perinatal tissues, cells, and secreted factors phrase.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.